Palm, Denise
Uzoni, Adriana
Simon, Frederick
Tucha, Oliver
Thome, Johannes
Faltraco, Frank
Funding for this research was provided by:
2020 FORUN (889024)
2020 CoCA ADHD Comorbidity (667302)
Universitätsmedizin Rostock
Article History
Received: 12 January 2021
Accepted: 27 June 2021
First Online: 18 July 2021
Declarations
:
: Johannes Thome has received financial support from pharmaceutical companies (Actelion, Astra Zeneca, Bristol-Myers Squibb, EVER Neuro Pharma GmbH, Janssen-Cilag, Lilly, Lundbeck, MEDICE, Merz, Novartis, Pfizer, Roche, Servier, Shire, Trommsdorff) some of which manufacture medication used in the treatment of ADHD patients. Frank Faltraco, Oliver Tucha, Frederick Simon, Adriana Uzoni and Denise Palm have no potential conflict of interest to disclose.
: Ethical approval for the conduct of the study, including obtaining human dermal biopsy samples, was given by the ethical review committee of Rostock University (Registration-number: A2013-159).
: Written consent was obtained from each study participant.
: Written consent was obtained from each study participant.